Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study
Publication
, Conference
Uy, GL; Avigan, D; Cortes, JE; Becker, PS; Chen, RW; Liesveld, JL; Hewes, B; Johns, D; Erba, HP
Published in: BLOOD
November 18, 2011
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 18, 2011
Volume
118
Issue
21
Start / End Page
39 / 40
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Uy, G. L., Avigan, D., Cortes, J. E., Becker, P. S., Chen, R. W., Liesveld, J. L., … Erba, H. P. (2011). Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study. In BLOOD (Vol. 118, pp. 39–40). San Diego, CA: AMER SOC HEMATOLOGY.
Uy, Geoffrey L., David Avigan, Jorge E. Cortes, Pamela S. Becker, Robert W. Chen, Jane L. Liesveld, Becker Hewes, Don Johns, and Harry Paul Erba. “Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.” In BLOOD, 118:39–40. AMER SOC HEMATOLOGY, 2011.
Uy GL, Avigan D, Cortes JE, Becker PS, Chen RW, Liesveld JL, et al. Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study. In: BLOOD. AMER SOC HEMATOLOGY; 2011. p. 39–40.
Uy, Geoffrey L., et al. “Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.” BLOOD, vol. 118, no. 21, AMER SOC HEMATOLOGY, 2011, pp. 39–40.
Uy GL, Avigan D, Cortes JE, Becker PS, Chen RW, Liesveld JL, Hewes B, Johns D, Erba HP. Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study. BLOOD. AMER SOC HEMATOLOGY; 2011. p. 39–40.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 18, 2011
Volume
118
Issue
21
Start / End Page
39 / 40
Location
San Diego, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology